YOSEMITE and RHINE
暂无分享,去创建一个
Rishi P. Singh | N. Eter | P. Ruamviboonsuk | C. Wykoff | Z. Haskova | K. Csaky | C. Baumal | A. Chang | K. Basu | David Silverman | Kemal Asik | Hugh Lin | Carlos Quezada Ruiz | J. Willis | Francis Abreu | Paisan Ruamviboonsuk
[1] Sung Who Park,et al. Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema , 2020, Scientific Reports.
[2] Z. Haskova,et al. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration , 2020, JAMA ophthalmology.
[3] S. Fauser,et al. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration , 2020, JAMA ophthalmology.
[4] David F Williams,et al. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes , 2020, British Journal of Ophthalmology.
[5] C. Wykoff,et al. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. , 2020, Ophthalmology.
[6] Sung Who Park,et al. One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study , 2020, Ophthalmologica.
[7] P. Sanfilippo,et al. Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice , 2019, Ophthalmology and Therapy.
[8] F. Lum,et al. Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis. , 2019, Ophthalmology.
[9] Jennifer I. Lim,et al. Diabetic Retinopathy Preferred Practice Pattern®. , 2019, Ophthalmology.
[10] T. Hong,et al. Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia , 2019, Diabetes, metabolic syndrome and obesity : targets and therapy.
[11] C. Wykoff,et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. , 2019, Ophthalmology.
[12] David F Williams,et al. Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States. , 2018, Ophthalmology. Retina.
[13] S. Kiss,et al. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. , 2018, American journal of ophthalmology.
[14] Bianca S. Gerendas,et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA) , 2017, Ophthalmologica.
[15] C. Klein,et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases , 2016, EMBO molecular medicine.
[16] R. Adelman,et al. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature , 2016, British Journal of Ophthalmology.
[17] S. Sivaprasad,et al. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion , 2016, Clinical ophthalmology.
[18] A. Wenzel,et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study , 2015, British Journal of Ophthalmology.
[19] P. Kaiser,et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. , 2015, Ophthalmology.
[20] Carsten Framme,et al. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations , 2015, Retina.
[21] Jennifer K. Sun,et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.
[22] P. Kaiser,et al. Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.
[23] Nader Sheibani,et al. Diabetes and Retinal Vascular Dysfunction , 2014, Journal of ophthalmic & vision research.
[24] J. Sorof,et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema , 2013, Therapeutic advances in endocrinology and metabolism.
[25] S. Cousens,et al. Computerized repeating and averaging improve the test-retest variability of ETDRS visual acuity measurements: implications for sensitivity and specificity. , 2011, Investigative ophthalmology & visual science.
[26] Frank Bretz,et al. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests , 2011, Biometrical journal. Biometrische Zeitschrift.
[27] S. Sivaprasad,et al. Intersession Repeatability of Visual Acuity, Colour Vision, Contrast Sensitivity, Retinal Sensitivity Thresholds and Retinal Thickness in Mild Diabetic Retinopathy , 2011 .
[28] Francesco Bandello,et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.
[29] G. Rubin,et al. Intersession repeatability of visual acuity scores in age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.
[30] Beau B. Bruce,et al. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. , 2017, Ophthalmology.
[31] Thomas W. Gardner,et al. Diabetic Retinopathy and Diabetic Macular Edema. , 2016, Developments in ophthalmology.
[32] P. Kaiser,et al. Intravitreal A fl ibercept for Diabetic Macular Edema , 2014 .
[33] T. Sano,et al. [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.